The University of Barcelona (UB) is Spain's oldest and largest university, located in Barcelona, Catalonia. Founded in 1450, it is a leading European research university with significant contributions to neuroscience and neurodegenerative disease research.
The university is a major center for biomedical research in Spain and Europe, with strong programs in neurology, molecular biology, and translational neuroscience. Located in Catalonia's capital, UB benefits from collaborations with hospitals and research centers throughout the Barcelona area.
The University of Barcelona was founded in 1450, making it one of Europe's oldest universities. Over the centuries, the institution has evolved from a medieval university into a modern research powerhouse.
The Faculty of Medicine was established in the 19th century and has since become one of Spain's leading medical schools. The development of neuroscience as a research priority began in the late 20th century, with the establishment of the Institute of Neurosciences and specialized research centers.
Today, UB maintains campuses throughout Barcelona, with major research facilities located in the historic center and the Biomedical Research Park (PRBB) on the seafront.
The Institute of Neurosciences at UB brings together researchers studying:
| Area | Key Researchers | Notable Contributions |
|---|---|---|
| Amyloid Biology | Dr. Javier Alegre | Aβ aggregation mechanisms [5] |
| Neuroinflammation | Dr. M. Escudero | Microglial activation in AD [6] |
| Tau Pathology | Dr. I. Ferrer | Tau isoforms in FTLD [1:1] |
| Prion Diseases | Dr. J. Castilla | Prion protein dynamics |
| Parkinson's Genetics | Dr. A. Fuerte | LRRK2 and GBA in Spanish populations [7] |
UB researchers investigate all aspects of AD pathogenesis:
Amyloid Biology: Studies on amyloid-beta aggregation, toxicity mechanisms, and therapeutic strategies [5:1]. The group has characterized amyloid metabolism in European populations.
Tau Pathology: Research on tau protein phosphorylation, aggregation, and spread [1:2]. Studies examine how tau propagates between neurons and contributes to neurodegeneration.
Neuroinflammation: Microglial activation and neuroinflammatory processes are major research areas [6:1]. Investigators study how inflammation contributes to disease and identify therapeutic targets [8].
Biomarkers: Development of CSF and blood biomarkers for early diagnosis and disease monitoring [9]. UB participates in European biomarker consortia.
Clinical Research: Clinical studies on MCI and early AD, including therapeutic trials and observational studies [10].
PD research at UB encompasses basic, translational, and clinical investigations.
Alpha-Synuclein Biology: Studies on alpha-synuclein aggregation, post-translational modifications, and propagation mechanisms [2:1].
Genetic Studies: Research on PD genetics in Spanish populations, including LRRK2 and GBA variants [7:1]. These studies reveal population-specific genetic architecture.
Clinical Research: Clinical trials of novel PD therapeutics and studies of disease progression [11].
Therapeutic Approaches: Development of disease-modifying therapies, including neuroprotective compounds and cell therapy approaches [12].
ALS research focuses on understanding motor neuron degeneration and developing interventions.
TDP-43 Pathology: Studies on TDP-43 protein aggregates that characterize most ALS cases.
Therapeutic Targets: Identification and validation of novel therapeutic targets [3:1].
Biomarkers: Development of biomarkers for early diagnosis and disease monitoring.
Research also encompasses:
The Center for Molecular Medicine (CiMM) at UB provides:
Located on the Barcelona seafront, the PRBB houses multiple neuroscience research groups with access to:
Studies molecular mechanisms of neuronal function and dysfunction. Research spans synaptic physiology, neuronal signaling, and gene regulation.
Focuses on understanding protein aggregation, cell death mechanisms, and therapeutic approaches across multiple neurodegenerative diseases.
Translational research linking basic science discoveries to clinical applications. Includes biomarker development and clinical trial programs.
Research on aging processes and interventions to delay or prevent cognitive decline [13].
UB investigators study how misfolded proteins accumulate in neurodegenerative diseases:
Inflammatory processes in the brain are investigated across disease contexts:
Energy metabolism impairment is a research priority [15]:
Cellular clearance mechanisms are studied [16]:
Blood-brain barrier and vascular contributions to disease are investigated [17]:
Early synaptic changes in neurodegeneration are examined [18]:
Cell replacement approaches are under development [12:1]:
Viral vector approaches to deliver therapeutic genes are explored [19]:
Early diagnostic and disease monitoring markers are developed [14:1]:
Dr. Ignacio Ferrer's laboratory focuses on tau pathology and FTLD. The group has made seminal discoveries about tau isoform composition and aggregation.
Dr. Javier Alegre's group studies amyloid biology and develops therapeutic strategies targeting Aβ aggregation.
Dr. Alberto Fuerte investigates PD genetics in Spanish populations, characterizing LRRK2 and GBA variant frequencies and pathogenicity.
Dr. Rafael García-Lopera's laboratory studies microglial activation and the role of inflammation in neurodegeneration.
The University of Barcelona maintains active collaborations with:
European Networks:
US Institutions:
International Alzheimer's Research:
Other International Partners:
UB offers comprehensive training in neuroscience and neurodegeneration:
Graduate Education:
Clinical Training:
International Programs:
UB is developing personalized approaches to neurodegenerative disease treatment based on genetic and biomarker profiling specific to Spanish and European populations.
Increased focus on translating basic discoveries into clinical applications through enhanced industry partnerships and clinical trial infrastructure.
Expanded role in European neuroscience research initiatives and global collaborations.
Investment in advanced technologies including AI for drug discovery, advanced imaging, and single-cell analysis.
Ferrer I, et al. Tau pathology in European populations. Brain Pathol. 2021. ↩︎ ↩︎ ↩︎ ↩︎
Alegre-Abarrategui J, et al. Alpha-synuclein research in Europe. Neurobiol Aging. 2020. ↩︎ ↩︎
Gutierrez J, et al. Therapeutic targets in ALS. J Clin Invest. 2023. ↩︎ ↩︎
Gomez-Tortosa E et al. Lewy body disease research (2020). 2020. ↩︎ ↩︎
Martinez A, et al. Amyloid biology in European cohorts. Brain. 2024. ↩︎ ↩︎
García-Lopera R, et al. Microglial activation in neurodegeneration. Glia. 2019. ↩︎ ↩︎
Fuerte A, et al. Parkinson's disease genetics in Spanish populations. Mov Disord. 2022. ↩︎ ↩︎
Pérez V, et al. Neuroinflammation mechanisms in AD. Nat Neurosci. 2023. ↩︎ ↩︎
Molinuevo JL et al. Alzheimer disease biomarkers (2019). 2019. ↩︎
Rami L et al. MCI and Alzheimer disease (2020). 2020. ↩︎
Ortega A, et al. Clinical trials in Spanish populations. Mov Disord. 2023. ↩︎
Rodriguez L, et al. Stem cell therapy for PD. Stem Cells. 2024. ↩︎ ↩︎
Valero S, et al. Cognitive decline in aging populations. Lancet Neurol. 2023. ↩︎
Sanchez M, et al. Biomarker discovery in neurodegenerative diseases. Alzheimer's & Dementia. 2022. ↩︎ ↩︎
Serra M, et al. Mitochondrial dysfunction in neurodegeneration. Cell Metab. 2023. ↩︎
Vilchez G, et al. Autophagy in protein aggregation diseases. Autophagy. 2022. ↩︎
Navarro J, et al. Neurovascular changes in aging and disease. Nat Rev Neurol. 2022. ↩︎
Cruz M, et al. Synaptic dysfunction in AD. Nat Neurosci. 2023. ↩︎
Lopez P, et al. Gene therapy approaches for neurodegeneration. Mol Ther. 2024. ↩︎
Blasco R, et al. Novel PET tracers for neurodegeneration. Eur J Nucl Med Mol Imaging. 2024. ↩︎